4Levitt RC,Olckers A,Meyers S,et al.Evidence for the localization of a malignant hyperthermia susceptibility locus (M HS 2)to human chromosome 17q[J].Genomics,1992,14:562-566.
5Monnier N,Stieglitz P,Procaccio V,et al.Malignant hyperthermia susceptibility is associated with a mutation of the alpa-1 subunit of the hum an dihydr0pyridlne scensitive I type voltage dependent calci Hill channel receptor in skeletal muscle[J].Am J Hum Gener,1997,60:1316-1325.
7Robinson RI,Anetseder MJ,Brancadoro V,et al.Recent advances in the diagnosis of malignant hyperthermia susceptibility:How confident can we be of genetic testing[J].Eur J Hum Genet,2003,11(4):342-348.
8Sambuughin N,Sei Y,Gallagher KI,et al.North Americann Ilialignant hypertherm ia population:Screening of the ryanodine receptor gene and identification of novel mutation[J].Anesthesiology,2001,95:594-599.
9Sei Y,Sambuughin NN,Davis EJ,et al.Malignant hyperthermia in North America[J].Anesthesiology,2004,101:824-830.
10McCarthy TV,Healy JM,Heffrom JJ,et al.Localization of the malignant hyperthermia susceptibility locus to human chromosom e19q12-13.2[J].Nature,1990,343:562-564.
4Nicole M, Renee KH,Payen JF,et al. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology, 2002, 97 : 1067-1074.
5Girad T, Treves S, Voronkov E, et al. Molecular genetic testing of malignant hyperthermia susceptibility. Anesthesiology, 2004, 100: 1076- 1080.
6Robison R, Hopkins P, Carsana A, et al. Several interacting genes influence the malignant hyperthermia phenotype. Hum Genet, 2003, 112: 217-218.
7McCarthy TV, Quane KA, Lynch PJ. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat, 2000, 15 : 410-417.
8Feng W, Fessenden JD, Pessah IN, et al. Mutational analysis of putative calcium binding motifs within the skeletal ryanodine receptor isoform, RYR1. J Biol Chem, 2004, 279: 53028-53035.
9Nelson TE. Malignant hyperthermia: a pharmacogenetic disease of Ca^2+ regulation proteins. Current molecular medicine, 2002, 2: 347- 369.
10Brooksbank RL, Badenhorts ME, lsaacs Hyam,et al. Treatment of normal skeletal muscle with FK506 or rapamycin results in halothane-induced muscle contracture. Anesthesiology, 1998, 89: 693-698.
7Anetseder M, Hager M, Muller CR, et al. Diagnosis of susceptibility to malignant hyperthermia by use of a meta- bolic test [J]. Lancet, 2002,359 (18) : 1 579.
8Amin K,Kauffman CA. Fever of unknown origin: a strategic approach to this diagnostic dilemma [ J ]. Postgrad Med, 2003, 114(3) :69-75.
9Hirschmann JV. Fever of unknown origin in adults[ J]. Clin Infeet Dis, 1997,24( 3 ) :291-302.
10Shiohara T,Kano Y,Takahashi R,et al. Drug-induced hypersensitivity syndrome: recent advances in the diagnosis, pathogenesis and management[J]. Chem Immunol Allergy, 2012,97:122-138.